Biotech entity

Wu Yifang

Person

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Fosun Pharma, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.

Last mentioned: Mar 24, 2026

Entity pulse

Recent coverage · Wu Yifang

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Wu Yifang

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Fosun Pharma, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 1 Biotech story that mention Wu Yifang, all published on March 24, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Wu Yifang. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. 2025 Annual Results

    Fosun Pharma officially releases its full-year financial performance for 2025.

  2. US FDA Approval

    Key biosimilar assets receive final marketing authorization for the US market.

  3. CAR-T Expansion

    Yescarta receives expanded indication approval for second-line treatment in China.

  4. ADC Platform Milestone

    First internally developed ADC candidate enters Phase II clinical trials.

Stories mentioning Wu Yifang 1

Pharma Neutral

Fosun Pharma 2025 Results: Innovation Revenue Surges as Global Footprint Expands

Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.

2 sources

Source: manilatimes.net · thailand-business-news.com

Wu Yifang is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.